Research ArticleOriginal Article
Open Access

Clinical delineation of myasthenia gravis in the Kingdom of Bahrain

Mohamed F. Binfalah, Hussein H. Alhafnawi, Ahmed A. Jaradat, Eslam Shosha, Ali J. Alhilly, Firas K. Al Nidawi, Mariam M. Alhammadi, Moiz O. Bakhiet and Fatema M. Abdulla
Neurosciences Journal January 2022, 27 (1) 16-23; DOI: https://doi.org/10.17712/nsj.2022.1.20210096

References

  1. 1.↵
    1. Binks S,
    2. Vincent A,
    3. Palace J
    . Myasthenia gravis: a clinical-immunological update. J Neurol 2016; 263: 826–834.
    OpenUrl
  2. 2.↵
    1. Cortés-Vicente E,
    2. Álvarez-Velasco R,
    3. Segovia S,
    4. Paradas C,
    5. Casasnovas C,
    6. Guerrero-Sola A, et al.
    Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 2020; 94: e1171–e1180.
    OpenUrl
  3. 3.↵
    1. Lindstrom JM,
    2. Seybold ME,
    3. Lennon VA,
    4. Whittingham S,
    5. Duane DD
    . Antibody to acetylcholine receptor in myasthenia gravis. Neurology 1998; 51: 933.2–933-a.
    OpenUrl
  4. 4.↵
    1. Gilhus NE. Myasthenia Gravis
    . N Engl J Med 2016; 375: 2570–2581.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Deymeer F,
    2. Gungor-Tuncer O,
    3. Ylmaz V,
    4. Parman Y,
    5. Serdaroglu P,
    6. Ozdemir C, et al.
    Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007; 68: 609–611.
    OpenUrl
  6. 6.↵
    1. Jaretzki A,
    2. Barohn RJ,
    3. Ernstoff RM,
    4. Kaminski HJ,
    5. Keesey JC,
    6. Penn AS, et al.
    Myasthenia gravis: Recommendations for clinical research standards. Ann Thorac Surg 2000; 70: 327–334.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Cho EB,
    2. Min JH,
    3. Lee S,
    4. Yoon CW,
    5. Seok JM,
    6. Cho HJ, et al.
    Late-onset non-thymomatous myasthenia gravis: Comparison with early-onset and very late-onset myasthenia gravis. Neurol Asia 2017; 22: 123–131.
    OpenUrl
  8. 8.↵
    1. Fulvio B,
    2. Mantegazza R
    . European database for myasthenia gravis: A model for an international disease registry. Neurology 2014; 83: 189–191.
    OpenUrl
  9. 9.↵
    1. Hong Y,
    2. Li HF,
    3. Skeie GO,
    4. Romi F,
    5. Hao HJ,
    6. Zhang X, et al.
    Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients. J Neuroimmunol 2016; 298: 51–57.
    OpenUrl
  10. 10.↵
    1. Breiner A,
    2. Widdifield J,
    3. Katzberg HD,
    4. Barnett C,
    5. Bril V,
    6. Tu K
    . Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord 2016; 26: 41–46.
    OpenUrl
  11. 11.↵
    1. Blum S,
    2. Lee D,
    3. Gillis D,
    4. McEniery DF,
    5. Reddel S,
    6. McCombe P
    . Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 2015; 22: 1164–1169.
    OpenUrl
  12. 12.↵
    1. Westerberg E,
    2. Punga AR
    . Epidemiology of Myasthenia Gravis in Sweden 2006–2016. Brain Behav 2020; 10.
  13. 13.↵
    1. Al-Moallem MA,
    2. Alkali NH,
    3. Hakami MA,
    4. Zaidan RM
    . Myasthenia gravis: Presentation and outcome in 104 patients managed in a single institution. Ann Saudi Med 2008; 28: 341–345.
    OpenUrlPubMed
  14. 14.↵
    1. Jacob PC,
    2. Tharakan JT,
    3. Chand PR,
    4. Koul RL,
    5. Chacko AP
    . Clinical profile of myasthenia gravis in the Sultanate of Oman. Saudi Med J 2003; 24: 774–775.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Alanazy MH
    . Clinical features and outcomes of patients with myasthenia gravis. Neurosciences 2019; 24: 176–184.
    OpenUrl
  16. 16.↵
    1. Malik YM,
    2. Dar JA,
    3. Almadani AA
    . Role of Myasthenia Gravis Auto-Antibodies as Predictor of Myasthenic Crisis and Clinical Parameters. J Neurol Neurosci 2019; 10: 1–6.
    OpenUrl
  17. 17.↵
    1. Tomschik M,
    2. Hilger E,
    3. Rath J,
    4. Mayer EM,
    5. Fahrner M,
    6. Cetin H, et al.
    Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 2020; 95: e1426–e1436.
    OpenUrl
  18. 18.↵
    1. Lee KW,
    2. Kim JS,
    3. Lee SH
    , and MG Study Group. Epidemiological and Clinical Characteristics of Myasthenia Gravis in Korea. J Korean Neurol Assoc 1997; 15: 825–838.
    OpenUrl
  19. 19.↵
    1. Avidan N,
    2. Le Panse R,
    3. Berrih-Aknin S,
    4. Miller A
    . Genetic basis of myasthenia gravis - A comprehensive review. J Autoimmun 2014; 52: 146–153.
    OpenUrl
  20. 20.↵
    1. Koneczny I,
    2. Cossins J,
    3. Vincent A
    . The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat 2014; 224: 29–35.
    OpenUrlCrossRef
  21. 21.
    1. Park KH,
    2. Waters P,
    3. Woodhall M,
    4. Lang B,
    5. Smith T,
    6. Sung JJ, et al.
    Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features. PLoS One 2018; 13: e0193723.
    OpenUrl
  22. 22.↵
    1. Oh SJ,
    2. Morgan MB,
    3. Lu L,
    4. Hatanaka Y,
    5. Hemmi S,
    6. Young A, et al.
    Racial differences in myasthenia gravis in Alabama. Muscle and Nerve 2009; 39: 328–332.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Hehir MK,
    2. Hobson-Webb LD,
    3. Benatar M,
    4. Barnett C,
    5. Silvestri NJ,
    6. Howard JF, et al.
    Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology 2017; 89: 1069–1077.
    OpenUrl
  24. 24.
    1. Tannemaat MR,
    2. Verschuuren JJGM
    . Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscul Disord 2020; 30: 111–119.
    OpenUrl
  25. 25.↵
    1. Guptill JT,
    2. Sanders DB,
    3. Evoli A
    . Anti-MuSK antibody Myasthenia gravis: Clinical findings and response to treatment in two large cohorts. Muscle and Nerve 2011; 44: 36–40.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Wolfe GI,
    2. Kaminski HJ,
    3. Aban IB,
    4. Minisman G,
    5. Kuo H-C,
    6. Marx A, et al.
    Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med 2016; 375: 511–522.
    OpenUrlPubMed
  27. 27.↵
    1. Baggi F,
    2. Andreetta F,
    3. Maggi L,
    4. Confalonieri P,
    5. Morandi L,
    6. Salerno F, et al.
    Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 2013; 80: 188–195.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Sanders DB,
    2. Wolfe GI,
    3. Benatar M,
    4. Evoli A,
    5. Gilhus NE,
    6. Illa I, et al.
    International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87: 419–425.
    OpenUrlPubMed
  29. 29.↵
    1. Goswami A,
    2. Baruah AR
    . Giant thymolipoma: A rare case presentation. Asian Cardiovasc Thorac Ann 2017; 25: 143–145.
    OpenUrl
  30. 30.↵
    1. Rieker RJ,
    2. Schirmacher P,
    3. Schnabel PA,
    4. Moser K,
    5. Hoffmann H,
    6. Dienemann H, et al.
    Thymolipoma. A report of nine cases, with emphasis on its association with myasthenia gravis. Surg Today 2010; 40: 132–136.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Othman SA,
    2. Alfrayyan OY,
    3. Alghamdi ZM,
    4. Makhdom F,
    5. Aljehani Y,
    6. Elbawab HY, et al.
    Thymolipoma association with myasthenia gravis: Case report. Am J Case Rep 2020; 21: e923989-1–e923989-4.
    OpenUrl
  32. 32.↵
    1. Tsukioka T,
    2. Inoue K,
    3. Iwata T,
    4. Mizuguchi S,
    5. Morita R,
    6. Suehiro S
    . Thymolipoma associated with myasthenia gravis. Gen Thorac Cardiovasc Surg 2007; 55: 26–28.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Huang CS,
    2. Li WY,
    3. Lee PC,
    4. Kao KP,
    5. Chou TY,
    6. Wu MH, et al.
    Analysis of outcomes following surgical treatment of thymolipomatous myasthenia gravis: Comparison with thymomatous and non-thymomatous myasthenia gravis. Interact Cardiovasc Thorac Surg 2014; 18: 475–481.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Huang X,
    2. Li Y,
    3. Feng H,
    4. Chen P,
    5. Liu W
    . Clinical characteristics of juvenile myasthenia gravis in Southern China. Front Neurol 2018; 9: 1–7.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Barraud C,
    2. Desguerre I,
    3. Barnerias C,
    4. Gitiaux C,
    5. Boulay C,
    6. Chabrol B
    . Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle and Nerve 2018; 57: 603–609.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section